SecurityLJPC / La Jolla Pharmaceutical Co. (503459604)
IndustryBiological Products, Except Diagnostic Substances (Biotech)
Common Shares Outstanding26,226,201 shares (as of 2018-06-30)
Total Insiders15
Total Directors6
Total Officers5

Stock Insider Trading (from SEC Form 4)

La Jolla Pharmaceutical Co. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

LJPC / La Jolla Pharmaceutical Co. insiders include PERCEPTIVE ADVISORS LLC, Rosen Robert, TANG CAPITAL MANAGEMENT LLC, Douglass Laura L., TIDMARSH GEORGE F, Rolke James, Johnson Craig A, Chawla Lakhmir S, EDELMAN JOSEPH, and TANG KEVIN C, CARVER JENNIFER, Zarrabian Saiid TANG CAPITAL PARTNERS LP, PERCEPTIVE LIFE SCIENCES MASTER FUND LTD, MULROY DENNIS, .

Insider Roster

Insider Dir Off 10% Shares Owned
Rolke James Chief Scientific Officer
X 74,328
CARVER JENNIFER Chief Operating Officer
X 6,500
Douglass Laura L. Director
X 500
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD 10% Owner
PERCEPTIVE ADVISORS LLC 10% Owner
EDELMAN JOSEPH 10% Owner
X 4,313,611
TANG CAPITAL MANAGEMENT LLC 10% Owner
TANG CAPITAL PARTNERS LP 10% Owner
TANG KEVIN C Director, 10% Owner
X 4,138,893
TANG KEVIN C Director, 10% Owner
TANG CAPITAL PARTNERS LP 10% Owner
TANG CAPITAL MANAGEMENT LLC 10% Owner
X X 3,590,419
EDELMAN JOSEPH 10% Owner
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD 10% Owner
PERCEPTIVE ADVISORS LLC 10% Owner
X 3,613,611
PERCEPTIVE ADVISORS LLC 10% Owner
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD 10% Owner
EDELMAN JOSEPH 10% Owner
X 3,563,611
Chawla Lakhmir S Chief Medical Officer
X
MULROY DENNIS Chief Financial Officer
X
TIDMARSH GEORGE F President, CEO & Secretary, Director
X X
Johnson Craig A Director
X
Rosen Robert Director
X
TANG CAPITAL PARTNERS LP 10% Owner
TANG KEVIN C Director, 10% Owner
TANG CAPITAL MANAGEMENT LLC 10% Owner
X
Zarrabian Saiid Director
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-08-16 4 CARVER JENNIFER P D 20.8954 1,000 6,500 135,820
2018-08-16 4 Rolke James P D 21.997 1,000 74,328 1,634,993
2018-05-30 4 Douglass Laura L. M D 6 500 500
2018-03-15 4 PERCEPTIVE ADVISORS LLC P I 29.50 700,000 4,313,611 127,251,524
2018-03-15 4 TANG KEVIN C By LP P I 29.50 508,474 4,138,893 122,097,344
2018-03-02 4 TANG KEVIN C By LP P I 30.4435 10,000 3,630,419 110,522,661
2018-02-28 4 TANG KEVIN C By LP P I 30.154 10,000 3,620,419 109,170,115
2018-02-28 4 TANG KEVIN C By LP P I 30.1171 10,000 3,610,419 108,735,350
2018-02-28 4 TANG KEVIN C By LP P I 29.5381 10,000 3,600,419 106,349,536
2018-02-23 4 CARVER JENNIFER P D 32.475 1,000 5,500 178,612
2018-02-27 4 TANG KEVIN C By LP P I 30.6037 10,000 3,590,419 109,880,106
2018-02-27 4 TANG KEVIN C By LP P I 30.688 10,000 3,580,419 109,875,898
2018-02-27 4 TANG KEVIN C By LP P I 30.8725 10,000 3,570,419 110,227,761
2018-02-27 4 TANG KEVIN C By LP P I 30.8796 10,000 3,560,419 109,944,315
2018-02-27 4 TANG KEVIN C By LP P I 30.5714 10,000 3,550,419 108,541,279
2018-02-27 4 TANG KEVIN C By LP P I 32.1728 10,000 3,540,419 113,905,192
2018-02-27 4 TANG KEVIN C By LP P I 32.6982 9,000 3,530,419 115,438,347
2018-02-26 4 TANG KEVIN C By LP P I 32.502 1,000 3,521,419 114,453,160
2018-02-26 4 TANG KEVIN C By LP P I 32.4821 10,000 3,520,419 114,350,602
2018-02-26 4 TANG KEVIN C By LP P I 32.916 10,000 3,510,419 115,548,952
2018-02-23 4 TANG KEVIN C By LP P I 32.3046 10,000 3,500,419 113,079,636
2018-02-23 4 TANG KEVIN C By LP P I 32.58 20,000 3,490,419 113,717,851
2018-02-23 4 TANG KEVIN C By LP P I 32.4186 10,000 3,470,419 112,506,125
2018-02-23 4 TANG KEVIN C By LP P I 31.9442 10,000 3,460,419 110,540,317
2018-02-23 4 TANG KEVIN C By LP P I 31.5413 10,000 3,450,419 108,830,701
2018-02-15 4 PERCEPTIVE ADVISORS LLC P I 32.42 50,000 3,613,611 117,153,269
2018-02-14 4 PERCEPTIVE ADVISORS LLC P I 32.69 100,000 3,563,611 116,494,444
2018-02-13 4 PERCEPTIVE ADVISORS LLC P I 32.75 75,000 3,463,611 113,433,260
2017-12-29 4 Douglass Laura L. S D 32.3208 -10,000 0
2017-12-29 4 Douglass Laura L. M D 6 4,000 10,000
2017-12-29 4 Douglass Laura L. M D 10.84 6,000 6,000
2017-12-27 4 CARVER JENNIFER P D 33.215 1,000 4,500 149,468
2017-03-23 4 TANG KEVIN C By LP P I 33.50 149,254 3,440,419 115,254,036
2017-03-02 4 CARVER JENNIFER P D 34.435 300 3,500 120,522
2017-03-02 4 CARVER JENNIFER P D 34.4455 300 3,200 110,226
2017-03-02 4 CARVER JENNIFER P D 34.489 400 2,900 100,018
2017-03-03 4 TIDMARSH GEORGE F P D 34.15 1,000 1,354,086 46,242,037
2017-03-02 4 TIDMARSH GEORGE F P D 34.1773 2,000 1,353,086 46,244,826
2017-03-03 4 Chawla Lakhmir S P D 34.4799 1,000 2,085 71,891
2017-03-02 4 Chawla Lakhmir S P D 35.3299 600 1,085 38,333
2017-03-02 4 TANG KEVIN C By LP P I 34.6384 100,000 3,291,165 114,000,690
2017-03-03 4 MULROY DENNIS P D 33.95 500 500 16,975
2016-12-28 4 TIDMARSH GEORGE F G D -74,000 1,373,086
2016-09-13 4 TANG KEVIN C By LP P I 20.2769 16,448 3,191,165 64,706,934
2016-09-12 4 TANG KEVIN C By LP P I 19.9179 22,587 3,174,717 63,233,696
2016-09-09 4 TANG KEVIN C By LP P I 19.7197 100,000 3,152,130 62,159,058
2016-03-04 4 TANG KEVIN C By LP P I 19.8464 20,000 3,052,130 60,573,793
2016-03-01 4 TIDMARSH GEORGE F P D 16.50 1,000 2,871,172 47,374,338
2016-03-01 4 TIDMARSH GEORGE F P D 16.64 1,000 2,871,172 47,776,302
2016-03-03 4 TANG KEVIN C By LP P I 18.9096 13,500 29,583,772 559,417,295
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related News Stories

Stocks To Watch: Time To Talk Valuation

2018-09-01 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (298-9)

7 Biotech Stocks Insiders Are Loading Up On

2018-08-22 247wallst
Biotechnology stocks have a reputation for being some of the most speculative, most volatile stocks out there. Investors and would-be investors have to stay alert to avoid getting burned. One encouraging sign in any company is when insiders put their money where their mouth is and buy shares. Lately, some insiders at biotech companies have been doing just that, sometimes taking advantage of share price moves (not to mention buy windows opening up) in the wake of the release of quarterly reports. (24-12)

La Jolla Pharmaceutical Co (LJPC) CEO George Tidmarsh on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha
La Jolla Pharmaceutical Co (NASDAQ:LJPC) Q2 2018 Earnings Conference Call August 8, 2018 4:30 PM ET

Galectin Therapeutics IPF Patent Solidifies Platform Technology Status

2018-07-05 seekingalpha
Galectin Therapeutics (NASDAQ:GALT) announced on June 27th its patent for the method and treatment of Idiopathic Pulmonary Fibrosis (NYSEARCA:IPF). The significance of this patent was initially received as extremely positive by the market, but recent structural pressures like the option exercise of a key departing officer continued to weigh on the price. Based on the recent Form 4 Filings, the selling pressure has abated because the officers have simply run out of options to sell. (24-2)

2 Stable and 2 Speculative Biotech Stocks to Buy | InvestorPlace

2018-06-15 investorplace
Biotech stocks represent a peculiar conundrum. On one hand, they are scientifically the most exciting investment sector. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. But the industry is heavily marked with failures and agonizing disappointments. (7-1)